RxDoctor Payments Data

Narine Topaldjikian, MD

Family Medicine · Sherman Oaks, CANPI 1659805679

Payments from drug & device makers

$622in general payments, 2019–2025

Across 16 payments — averaging $38.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$214
  • Otsuka America Pharmaceutical, Inc.$175
  • Sanofi-aventis U.S. LLC$70
  • Intuitive Surgical$56
  • Hologic Sales And Service, LLC$32
  • Eisai Inc.$31
  • plus $44 from 2 others

What the payments were for

  • Travel & lodging$51%
  • Food & beverage$61799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$622 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$317,897
Medicare patients
139
Services billed
2,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide193$200,274
Zileuton ErZileuton60$131,053
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate88$86,806
Metformin Er GastricMetformin Hcl85$81,445
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag73$76,249
JardianceEmpagliflozin110$72,694
Diclofenac Sodium205$65,806
VascepaIcosapent Ethyl170$57,412
OzempicSemaglutide57$52,030
TrulicityDulaglutide42$42,112
Repatha SureclickEvolocumab73$40,171
LinzessLinaclotide74$38,513
CreonLipase/Protease/Amylase32$34,979
Mesalamine59$28,365
JanumetSitagliptin Phos/Metformin Hcl48$26,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$214$242,386235 claims
Novo NordiskOzempic$25$52,03057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Sherman Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →